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The identiﬁcation of tumor antigens which expression is essential for the survival of tumor cells is a new avenue to
prevent antigen loss variants emerging due to immunoselection, particularly during immune therapy. The
melanoma inhibitor of apoptosis protein, ML-IAP (also named livin) counteracts apoptosis induced by death
receptors, hypooxgenic conditions, or chemotherapeutic agents. Thus, elevated expression of ML-IAP renders
melanoma cells resistant to apoptotic stimuli and thereby potentially contributes to the oncogenic phenotype.
Here, we demonstrate that T cells in a large proportion of melanoma patients inﬁltrating the tumor or circulating in
the peripheral blood speciﬁcally recognize ML-IAP-derived peptides. Interestingly, the responses against the
peptide epitope ML-IAP280–289 were not restricted to melanoma patients but present among peripheral blood T cells
in a few healthy controls. In situ peptide/HLA-A2 multimer staining, however, conﬁrmed the inﬁltration of ML-IAP-
reactive cells into the tumor microenvironment. Moreover, ML-IAP-reactive T cells isolated by magnetic beads
coated with peptide/HLA-A2 complexes were cytotoxic against HLA-matched melanoma cells. In conclusion, out
data strongly indicate ML-IAP as a suitable target for immunologic intervention.
Key words: antigens/cytotoxic T lymphocytes/epitopes/human/peptides/tumor immunity.
J Invest Dermatol 122:392 –399, 2004
It is well established that peptide epitopes derived from
human tumor-associated antigens (TAA) can be recognized
by cytotoxic T lymphocytes (CTL) in the context of major
histocompatibility complex (MHC) molecules (Van den
Eynde and Boon, 1997) and that most—if not all—tumors
express such antigens. Consequently, several strategies
target these TAA in order to generate effective anti-tumor
CTL responses in patients (Heslop and Rooney, 1997;
Rosenberg et al, 1998; Thurner et al, 1999). Notably,
powerful CTL responses against these antigens have
indeed been induced by vaccination and some patients
experienced a complete remission of their disease (Rosen-
berg, 1996; Marchand et al, 1999). Immunoselection of
antigen loss variants, however, may be an important
obstacle for the curative potential of most of the known
CTL epitopes in clinical oncology as most characterized
peptides are derived from proteins, which are not essential
for the survival of the tumor cell. Thus, tumor cells lacking
the expression of the targeted antigen escape immune
surveillance (Becker et al, 1993; Cormier et al, 1998). CTL
epitopes derived from proteins, which are either linked to
the neoplastic transformation such as mutated tumor
suppressor genes or are essential for the survival of tumor
cells should not be inflicted by this form of immunoselec-
tion. We recently identified spontaneous T cell responses
against survivin in patients suffering from melanoma,
leukemia, or breast cancer (Andersen et al, 2001a,b).
Survivin is a member of the inhibitor of apoptosis protein
(IAP) family, and it is becoming evident that IAP expression
enhances the survival of cancer cells and facilitates their
escape from immune surveillance and cytotoxic therapies
(Jaattela, 1999; Zaffaroni et al, 2002). In addition to survivin,
a number of different IAP have been described. Their
different expression patterns suggest an organ-specific role
in promoting cell survival during development and tissue
homeostasis. Whereas X-IAP, C-IAP1, and C-IAP2 are
relatively ubiquitously expressed, survivin is expressed only
in fetal and tumor tissues. Similarly, ML-IAP has a rather
selective expression pattern, as it is predominantly de-
tected in melanoma and a limited number of other tissues
(Vucic et al, 2000; Kasof and Gomes, 2001). ML-IAP and
survivin seems to be the only IAP expressed in melanoma.
Whereas ML-IAP can be detected in the majority of
melanoma cell lines, it is not present in normal melanocytes
and high levels of ML-IAP are associated with resistance to
drug-induced apoptosis of melanoma cells (Vucic et al,
2000; Chen et al, 2003). Thus, ML-IAP is a critical cellular
factor as increased expression levels confer resistance to
apoptotic stimuli, thereby contributing to the pathogenesis
and progression of melanoma. These characteristics sug-
gest ML-IAP as a suitable target for immunotherapy against
cancer. In that regard, Schmollinger et al (2003), recently
anecdotally reported that a melanoma patient vaccinated
with irradiated autologous melanoma cells engineered to
Abbreviations: CLL, chronic lymphatic leukemia; CTL, cytotoxic T
lymphocytes; ML-IAP, melanoma inhibitor of apoptosis protein;
TAA, tumor-associated antigens; PBL, peripheral blood lympho-
cytes; TAP, transporter associated with antigen processing; TIL,
tumor-infiltrating lymphocytes.
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secrete granulocyte-macrophage colony-stimulating factor,
developed CTL reactivity against two ML-IAP-derived
peptides. In this study, we searched for and detected
spontaneous T cell reactivity in tumor-infiltrating lympho-
cytes (TIL) and peripheral blood lymphocytes (PBL) against
ML-IAP-derived peptides in a larger series of melanoma
patients by ELISPOT assay. Furthermore, we took advan-
tage of the recently established techniques allowing in situ
detection as well as ex vivo isolation of antigen-reactive T
cells to analyze the functional capacity of ML-IAP-specific
CTL.
Results
Binding of ML-IAP-derived peptides to HLA-A2 The
amino acid sequence of the ML-IAP protein was screened
for the most probable HLA-A2 nona-mer and deca-mer
peptide epitopes, using the main HLA-A2-specific anchor
residues (Andersen et al, 2000). Twelve ML-IAP deduced
peptides were synthesized and examined for binding to
HLA-A2 by comparison with the HLA-A2 high-affinity
positive control epitope from HIV-1 pol476–484 (ILKEPVHGV)
by the assembly assay. The assembly assay is based on
stabilization of the class I molecule after loading of different
concentrations of peptide to the TAP-deficient cell line T2.
Subsequently, correctly folded stable MHC heavy chains
are immunoprecipitated using conformation-dependent
antibodies. The extent of stabilization of class I MHC
molecules is directly related to the binding affinity of the
added peptide as exemplified in Fig 1. The peptide
concentration required for half maximal recovery of class I
MHC molecules (C50 value) were 0.2 mM for the HIV-1
pol476–484 (Table I). Five ML-IAP peptides bound with similar
high affinity as the positive control; ML-IAP245, ML-IAP90,
ML-IAP34, ML-IAP54, and ML-IAP99 (C50¼ 1, 0.2, 1, 1, and
0.9 mM, respectively) (Table I). The peptides ML-IAP280, ML-
IAP83, and ML-IAP154 bound only with intermediate affinity
(C50¼20, 30, and 10 mM, respectively), and ML-IAP230 and
ML-IAP98 bound only weakly to HLA-A2 (C504100 mM). Two
of the peptides examined (ML-IAP261, ML-IAP200) did not
bind to HLA-A2 at all (Table I).
CTL responses against ML-IAP-derived peptides in
melanoma patients Using the ELISPOT interferon-g secre-
tion assay, we examined for the presence of specific T cell
responses against the ML-IAP deduced, HLA-A2 binding
peptides in peripheral blood T cells and TIL from melanoma
patients. This method has previously been shown to be
highly effective to identify tumor-specific CTL in cancer
patients (Herr et al, 1999; Andersen et al, 2001a; Schei-
benbogen et al, 2002).
The strongest and most frequent CTL responses were
detected against the intermediate HLA-A2 binding peptide
ML-IAP280 and responses against this peptide were actually
present in both TIL and PBL. Figure 2(A) exemplifies such
strong spontaneous responses; each spot represents a
peptide-reactive, interferon-g producing cell. Additionally,
we examined PBL from 45 patients and TIL from 16 patients
for responses against ML-IAP280, identifying spontaneous
responses in PBL from 14 patients (  35%), and in TIL from
six patients (  43%) (Fig 2B).
Albeit less frequent, spontaneous CTL responses against
three additional ML-IAP-derived peptides were detected.
PBL from 37 patients and TIL from 20 patients were
examined for a response against ML-IAP245, ML-IAP90, and
ML-IAP230 revealing responses against the ML-IAP245
peptide in two of the PBL (  5%), and five of the TIL
samples (  25%) (Fig 3), and responses against the ML-
IAP90 peptide in two PBL (  5%), and seven TIL samples
(  35%) (Fig 3). Surprisingly, we also detected a response
against the weak HLA-A2 binding peptide ML-IAP230 in PBL
of two patients (  5%), and TIL of six patients (  30%)
Figure 1
Identification of HLA-A2-binding peptides from ML-IAP. Class I
MHC heavy chain bands were quantified on a PhosphorImager. The
mount of stabilized HLA-A2 heavy chain is directly related to the
binding affinity of the added peptide. The binding of the HLA-A2-
restricted-positive control peptide HIV Pol476 (black square) was
compared with the peptides ML-IAP90 (black triangle), ML-IAP230
(white square), ML-IAP245 (black circle), and ML-IAP280 (white circle).
Table I. Peptides examined in this study
Proteina Sequence C50 (mM)
b
HIV-1 pol476 ILKEPVHGV 0.2
ML-IAP245 RLQEERTCKV 1
ML-IAP280 QLCPICRAPV 20
ML-IAP90 RLASFYDWPL 0.2
ML-IAP154 LLRSKGRDFV 10
ML-IAP230 VLEPPGARDV 4100
ML-IAP98 PLTAEVPPEL 4100
ML-IAP261 SIVFVPCGHL Not binding
ML-IAP34 SLGSPVLGL 1
ML-IAP54 QILGQLRPL 1
ML-IAP99 LTAEVPPEL 0.9
ML-IAP83 GMGSEELRL 30
ML-IAP200 ELPTPRREV Not binding
aThe value range listed in subscript indicates the position of the first
amino acid in the sequence.
bThe C50 value is the concentration of the peptide required for half
maximal binding to HLA-A2.
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even though this peptide was not able to stabilize the HLA-
A2 molecule (Fig 3).
ML-IAP-reactive T cells in healthy individuals PBL from
10 healthy, HLA-A2-positive persons were analyzed to
investigate whether a response against ML-IAP245, ML-
IAP90, and ML-IAP230 would be present. No responses were
observed in any of the controls against any of these
peptides. As the spontaneous CTL responses against ML-
IAP280 were very frequent in melanoma patients, however,
we additionally examined 32 healthy individuals for re-
sponses against this peptide. Surprisingly, we detected a
response in four of these (Fig 4).
Detection of ML-IAP-reactive T cells in situ ML-IAP280/
HLA-A2 and ML-IAP245/HLA-A2-specific monomers were
multimerized using dextran molecules, which were con-
jugated with both streptavidin and fluorescein isothiocya-
nate. Multimerized MHC complexes were used to stain
acetone-fixed, frozen material as described previously
(Andersen et al, 2001b; Schrama et al, 2002) and antigen-
specific cells were visualized using a confocal laser
microscope. Sections of primary melanoma from six
patients were analyzed, and ML-IAP280- and ML-IAP245-
reactive CTL could readily be detected in situ in the tumor
microenvironment in two of the patients (Fig 5).
ML-IAP/HLA-A2-reactive CTL lyze HLA-matched mela-
noma cells To characterize the functional capacity of ML-
IAP-reactive CTL, these cells were isolated by means of
magnetic beads coated with HLA-A2/ML-IAP complexes.
Recently, we isolated gp100- and Mart-1-specific T cells in
a similar manner showing that this method is highly efficient
to enrich specifically peptide/MHC-reactive T cells (Schra-
ma et al, 2001). ML-IAP245-specific cells were directly
isolated from PBL (Fig 6A). ML-IAP280-reactive cells were
enriched from TIL of a melanoma infiltrated lymph node
after being stimulated once in vitro with peptide. These cells
Figure 2
T cell response against the ML-IAP280
(QLCPICRAPV) peptide. (A) Strong re-
sponses was seen in TIL from the melano-
ma patients Cmel72 and Cmel9 and in
PBL from the melanoma patient Cmel3. T
lymphocytes were stimulated once with
peptide before plated at 3  105 cells per
well in duplicates either with T2 cells with-
out (light gray) or with peptide (dark gray).
The graph depicts the quantification of
interferon-g producing cells. (B) Patients
hosting weaker ML-IAP280 responses. The
average number of ML-IAP280-specific cells
was calculated after subtraction of spots
without added peptide for each patient
using the ImmunoSpot Series 2.0 Analyzer
(CTL Analyzers, LLC). PBL from 45 mela-
noma patients and TIL from 16 patients was
examined. po0.05 (evaluated by Student’s
t test for unpaired samples) calculated as
the number of spots in wells with added
peptide as compared with the number of
spots in wells without peptide.
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lyzed T2-cells in a peptide-specific manner (Fig 6B).
Additionally, we tested the cytotoxicity of the ML-IAP280-
reactive CTL against the autologous melanoma line FM72,
the HLA-A2-matched melanoma cell line FM93 and the HLA
mismatched melanoma cell line FM56. This analysis
revealed that the ML-IAP280-reactive T cells efficiently lyzed
both the autologous and the HLA-matched melanoma cell
lines. In contrast, no cytotoxicity was observed against the
HLA-A2-negative melanoma cell line FM56 or the natural
killer target cell K562 (Fig 6C).
Discussion
In order to define new targets for specific immunotherapy,
we scanned the ML-IAP protein for the presence of HLA-A2
binding motifs and—after successful identification—used
these peptides to test for the presence of specific T cell
reactivities in melanoma patients (n¼55) by ELISPOT
assay. Following this strategy, we identified strong CTL
responses against the intermediate HLA-A2 binding peptide
ML-IAP280, as well as intermediate responses to three
additional peptide epitopes, i.e., the strong HLA-A2 binding
peptides ML-IAP245 and ML-IAP90 and the very weak
binding peptide ML-IAP230. Notably, the ML-IAP90 was also
identified as an epitope in the one melanoma patient
examined by Schmollinger et al (2003).
Vucic et al (2000) demonstrated by data from northern
blot analysis that elevated levels of ML-IAP can be detected
in melanoma cells, but not in normal tissue, except to some
extent in the testis. This were supported by Kasof and
Gomes (2001), who were able to detect elevated levels of
ML-IAP in a large panel of melanoma cells, whereas they
could not detect ML-IAP in healthy melanocytes or any
normal tissues except placenta. Responses against one of
the identified epitopes, ML-IAP280, however, were not only
detected in a large proportion of the melanoma patients,
but also in a limited number of healthy individuals. The
significance of this finding is unclear, as neither of the
healthy donors included in the study showed any signs of
autoimmunity despite the fact that they hosted a T cell
response against ML-IAP. In that regard, it is well estab-
lished that circulating precursor CTL against melanocyte
Figure 3
T cell response against the peptides
ML-IAP245 (RLQEERTCKV), ML-IAP230
(VLEPPGARDV), and ML-IAP90 (RLAS-
FYDWPL). TIL samples from 20 patients
and in PBL from 37 melanoma patients
were analyzed. T lymphocytes were
stimulated once with peptide before
plated at 3  105 cells per well in
duplicates either without or with pep-
tide. The average number of peptide-
specific spots (after subtraction of spots
without added peptide) was calculated
for each patient using the ImmunoSpot
Series 2.0 Analyzer (CTL Analyzers,
LLC). po0.05 (evaluated by Student’s t
test for unpaired samples) calculated as
the number of spots in wells with added
peptide as compared with the number
of spots in wells without peptide.
Figure 4
T cell response against the peptide ML-IAP280 (QLCPICRAPV) in
healthy individuals. PBL from 34 HLA-A2-positive, healthy individuals
were analyzed. T lymphocytes were stimulated once with peptide
before plated at 3  105 cells per well in duplicates either without or
with peptide. The average number of peptide-specific spots (after
subtraction of spots without added peptide) was calculated for each
patient using the ImmunoSpot Series 2.0 Analyzer (CTL Analyzers,
LLC). po0.05 (evaluated by Student’s t test for unpaired samples)
calculated as the number of spots in wells with added peptide as
compared with the number of spots in wells without peptide.
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differentiation antigens, such as MART-1/Melan-A, gp100,
and tyrosinase can be detected not only in melanoma
patients but also in some normal donors (Ja¨ger et al, 1996;
D’Souza et al, 1998; Griffioen et al, 2001). Interestingly,
major differences in the differentiation status of circulating
CTLp to the immunodominant Melan-A26-35 epitope of
melanoma patients and healthy individuals have been
reported. In contrast to the latter, patients with metastatic
melanoma Melan-A-specific CTLp are characterized by a
memory phenotype (D’Souza et al, 1998).
It should be noted that we were able to detect ML-IAP-
reactive CTL not only in circulation but also in the
inflammatory infiltrate of the tumor. There is a consensus
that effective tumor immunity requires proper priming of the
T cell. It is equally important, however, that the T cells
acquire the ability to home to the site of action. The
combined detection of ML-IAP-specific T cells in the blood
and in the tumor lesions indicates that these cells are
capable of circulating and homing to the tumor site. This is a
significant finding, as several clinical reports have sug-
gested a functional dissociation between local and systemic
anti-melanoma Tcell responses. Thus, the presence of TAA-
specific T cells in circulation may not lead to clinically
relevant responses (Lee et al, 1998; Rosenberg et al, 1998;
thor Straten et al, 1999).
The ELISPOT methodology represents a strong tool to
monitor peptide-specific T cell responses. Although it has
been shown that ELISPOT reactivity in most cases
correlates with the capacity to lyze the target cell, the
formal prove for this notion can only be obtained directly.
We provided such evidence by isolation of ML-IAP-reactive
T cells, which possess the functional capacity of peptide-
specific target cell lysis. Moreover, ML-IAP-reactive T cells
killed not only the autologous tumor cell line, but also a
HLA-matched melanoma cell line. This finding further
suggests that melanoma cells indeed process and present
the ML-IAP peptide.
Two of the epitopes identified (ML-IAP280 and ML-IAP230)
only weakly bound to HLA-A2. In that respect, it is worth
noting that many factors may influence the CTL response
against any given peptide. These include expression level of
the relevant source protein, processing, TAP transport,
peptide affinity to the class I MHC molecule, surface
expression of the class I MHC, T cell receptor repertoire,
etc. (Yewdell and Bennink, 1999). Thus, peptide binding to
class I is only one in a number of factors that determine the
immunogenicity of a given peptide. Additionally, in contrast
to foreign peptides, self peptides expressed on the cell
surface at high density due to high MHC-binding affinity,
seem rather to induce tolerance as reactive T cells are
eliminated or inactivated (Moudgil and Sercarz, 1994). Thus,
many prominent epitopes for CTL responses to self proteins
are subdominant or cryptic. This notion is substantiated by
the observation that many epitopes of melanoma antigens,
which are nonmutated self proteins, such as gp100 and
MART-1, have relatively low binding affinities to class I MHC
(Parkhurst et al, 1996). As the efficacy of tumor immu-
notherapy largely depends on the avidity of recruited CTL,
rather than the affinity of the epitope to the MHC molecule
(Zeh et al, 1999), low-affinity epitopes from oncogenic
nonmutated self proteins are suitable targets, provided that
they are presented by tumor cells efficiently enough to be
recognized by CTL. For ML-IAP280 we directly demon-
strated this by direct cytotoxicity assays and in situ
multimer staining.
The attractiveness of using IAP such as ML-IAP and/or
survivin for vaccination purposes is based on the fact that
downregulation or loss of expression of these proteins as
some form of immune escape would impair sustained tumor
growth. For therapeutic strategies, targeting of antigens that
plays an insignificant role in relation to tumor cell growth
and survival, the selection of antigen deficient tumors is a
well-recognized limitation (Ja¨ger et al, 1997; Thurner et al,
1999; Yee et al, 2000). As elevated expression of ML-IAP in
Figure 5
In situ detection of ML-IAP-reactive
CTL. Confocal laser scanning micro-
scopy was used to detect CTL reacting
with a Cy3-conjugated anti-CD8 anti-
body (red channel) and a fluorescein
isothiocyanate-conjugated multimeric
HLA-A2/ML-IAP280 construct (green
channel) (first and second columns) or
with a fluorescein isothiocyanate con-
jugated multimeric HLA-A2/ML-IAP245
construct (last column) in primary tu-
mors from two HLA-A2-positive mela-
noma patients.
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cells is correlated with drug resistance (Vucic et al, 2000;
Ashhab et al, 2001), the combination of a ML-IAP-based
immunotherapy with cytotoxic chemotherapy might be an
effective way to treat cancer.
In conclusion, we demonstrate that IAP represents a
novel group of proteins of tumor antigens in cancer patients
recognized by cytotoxic T cells. Thus, proteins that confer
the oncogenic phenotype of tumor cells may serve as
targets for immune responses. Our data thereby stress the
importance of combining the conceptual understanding of
cellular immunity with the phenotypic characteristics of
cancer cells.
Materials and Methods
Patients and normal control PBL or T lymphocytes from tumor
infiltrated lymph nodes were obtained from HLA-A2 positive
melanoma patients or healthy individuals. Informed consent was
otained from the patients prior to any of these measures.
Peptides All peptides were purchased from KJ Ross-Petersen
APS (Holte, Denmark) and provided at more than 80% purity as
verified by high-performance liquid chromatography and mass
spectrometry analysis. All peptides used are listed in Table I.
Assembly assay for peptide binding to class I MHC molecu-
les Assembly assays for binding of the synthetic peptides to class
I MHC molecules metabolically labeled with [35S]-methionine were
carried out as described (Andersen et al, 1999a,b). The assembly
assay is based on stabilization of the class I molecule after loading
of peptide to the peptide transporter deficient cell line T2.
Subsequently, correctly folded stable MHC heavy chains are
immunoprecipitated using conformation-dependent antibodies.
After IEF electrophoresis, gels were exposed to PhosphorImager
screens, and peptide binding was quantitated using the Image-
quant PhosphorImager program (Molecular Dynamics, Sunnyvale,
California).
Antigen stimulation of PBL To extend the sensitivity of the
ELISPOT assay, PBL were stimulated once in vitro prior to analysis
(McCutcheon et al, 1997; Pass et al, 1998). At day 0, PBL or
crushed lymph nodes were thawed and plated in 2 mL per well at a
concentration of 2  106 cells in 24-well plates (Nunc, Denmark) in
X-vivo medium (BioWhittaker, Walkersville, Maryland), 5% heat-
inactivated human serum, and 2 mM of L-glutamine in the
presence of 10 mM of peptide. Two days later 20 IU per mL
recombinant interleukin-2 (Chiron, Ratingen, Germany) was added
to the cultures. The cultured cells were tested for reactivity in the
ELISPOT on day 12.
ELISPOT assay The ELISPOT assay was used to quantify peptide
epitope-specific interferon-g releasing effector cells as described
previously (Berke et al, 2000). Briefly, nitrocellulose bottomed
96-well plates (MultiScreen MAIP N45, Millipore, Hedehusene,
Denmark) were coated with anti-interferon-g antibody (1-D1K,
Mabtech, Nacka, Sweden). The wells were washed, blocked by X-
vivo medium, and cells added in duplicates at different cell
concentrations. Peptides were then added to each well and the
plates were incubated overnight. The following day, media was
discarded and the wells were washed prior to addition of
biotinylated secondary antibody (7-B6-1-Biotin, Mabtech). The
plates were incubated for 2 h, washed, and avidin–enzyme
conjugate (AP-Avidin, Calbiochem, Life Technologies, Roskilde,
Denmark) was added to each well. Plates were incubated at room
temperature for 1 h and the enzyme substrate NBT/BCIP (Gibco,
Life Technologies, Roskilde, Denmark) was added to each well and
incubated at room temperature for 5 to 10 min. The reaction was
terminated by washing with tap-water upon the emergency of dark
purple spots. The spots were counted using the ImmunoSpot
Series 2.0 Analyzer (CTL Analyzers, LLC, Cleveland, Ohio) and the
peptide-specific CTL frequency could be calculated from the
numbers of spot-forming cells. All assays were performed in
duplicates for each peptide antigen.
Figure 6
Cytolytic capacity of ML-IAP-specific CTL. (A) ML-IAP245-reactive
CTL were isolated from PBL from the melanoma patients CmelE22
using peptide-coated magnetic beads before being plated at 2  103
cells per well in duplicates either with T2 cells without or pulsed with
ML-IAP245. (B) ML-IAP280-reactive CTL were isolated from a melano-
ma-infiltrated lymph node from patient Cmel72 using peptide-coated
magnetic beads. These cells was analyzed for specific lysis of T2 cells
with (square) or without (triangle) ML-IAP280 peptide. (C) Lysis by ML-
IAP280-isolated T cells of the autologous melanoma cell line FM72
(square), the HLA-A2-positive melanoma cell line FM93 (triangle), the
HLA-A2 negative cell line FM56 (black circle) and the natural killer target
cell line K562 (white circle).
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Immunohistochemistry stainings Multimerized peptide/HLA
complexes were used to identify antigen-specific T cells in situ in
tumor lesions of cancer patients, as previously described
(Anderson et al, 2001b). Biotinylated ML-IAP280/HLA-A2 and ML-
IAP245/HLA-A2 monomer was supplied by Proimmune Ltd (Oxford,
UK). The biotinylated monomers were multimerized with strepta-
vidin–fluorescein isothiocyanate-conjugated dextran molecules
(kindly provided by L. Winther, DAKO, Glostrup, Denmark) to
generate multivalent HLA-dextran compounds for immunohisto-
chemistry. Tissue sections were dried overnight and subsequently
fixed in cold acetone for 5 min. All incubation steps were
performed in the dark at room temperature: (1) 45 min of the
primary antibody (1:100 diluted); (2) Cy3-conjugated goat anti-
mouse (1:500 diluted; code 115-165-100; Jackson ImmunoRe-
search, obtained from Dianova, Hamburg, Germany) for 45 min;
and, finally, (3) the multimers for 75 min. Between each step, the
slides were washed two times for 10 min in phosphate-buffered
saline/bovine serum albumin 0.1%. The slides were mounted in
Vectashield and kept in the refrigerator until observed under the
confocal microscope (TCS 4D, Leica, Mannheim, Germany).
Isolation of peptide-speciﬁc T cells Antigen-specific cells were
isolated by means of ML-IAP280/HLA-A2- and ML-IAP245/HLA-A2-
coated magnetic beads as previously described (Anderson et al,
2001b). Biotinylated monomers (ProImmune, Oxford, UK) were
coupled to streptavadin coated magnetic beads (Dynabeads M-
280, Dynal A/S, Oslo, Norway) by incubating 2.5 mg monomers with
5  106 beads in 40 mL phosphate-buffered saline, for 20 min at
room temperature. The magnetic complexes were washed three
times in phosphate-buffered saline in a magnetic field (Dynal A/S)
and subsequently mixed with PBL, at a ratio of 1:10 in phosphate-
buffered saline with 5% bovine serum albumin, and rotated very
gently for 1 h. Antigen-specific CD8þ T cells associating with the
magnetic complexes were gently washed three times. Isolated
cells were resuspended numerous times in X-vivo with 5% human
serum, and incubated for 2 h, before the magnetic beads were
released and removed from the cell suspension. The isolated cells
were cultured in a 96-well plate in X-vivo with 5% 5% human
serum. One day after isolation 20 units interleukin-2 per mL was
added, and on day 5 the capacity of these cells to kill target cells
was tested either by ELISPOT or in standard 51Cr release assays.
Cytotoxicity assay Conventional [51Cr]-release assays for CTL-
mediated cytotoxicity was carried out as described elsewhere
(Andersen et al, 1999a). Target cells were T2 cells with or without
the relevant peptide, autologous melanoma cell line FM72, the
HLA-A2-positive melanoma cell line FM93 (Kirkin et al, 1995), and
the HLA-A2 negative melanoma cell line FM56 (Kirkin et al, 1995).
All cancer cell lines expressed ML-IAP as examined by reverse
transcription–polymerase chain reaction (data not shown).
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